首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1944404

全球細胞健康篩檢市場：按樣本類型、檢體技術、組件類型、應用領域、最終用戶、國家和地區分類－產業分析、市場規模、佔有率和預測（2025-2032）

Cellular Health Screening Market, By Sample Type, By Testing Technology, By Component Type, By Applications Area, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日期: 2026年02月26日 | 出版商:

AnalystView Market Insights | 英文 338 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年細胞健康篩檢市場規模價值為 32.9809 億美元，從 2025 年到 2032 年將以 9.45% 的複合年成長率成長。

細胞健康篩檢是一種從分子和功能層面分析細胞，以檢測異常、監測細胞健康狀況並指南治療性介入的技術。對疾病早期檢測、個人化醫療和藥物研發日益成長的需求正在推動細胞健康篩檢技術的應用。開發高通量、精準且非侵入性的篩檢平台對於癌症診斷、感染疾病檢測和精準醫療應用至關重要，並且蘊藏著巨大的發展機會。目前，將自動化和基於人工智慧的分析方法相結合以提高效率和準確性已成為一種顯著趨勢。然而，高成本和複雜的流程，尤其是在高級分子和影像篩檢方面，限制了其在小規模診所和新興地區的廣泛應用。

細胞健康篩檢市場動態

擴大個人化醫療的普及範圍

精準醫療是指根據患者的基因資訊、生物標記和個人健康數據來客製化醫療方案。它專注於提供標靶治療和精準干預，以改善治療效果並減少副作用。先進的醫療診斷技術和個人化醫療的日益普及，顯著推動了對細胞健康篩檢技術的需求，這些技術在疾病早期檢測、患者健康監測和治療指南中發揮關鍵作用。隨著醫療機構越來越重視精準醫療和預防醫學，實驗室和診所迫切需要準確、高通量且可靠的篩檢平台，這些平台能夠透過深入的細胞分析、生物標記檢測和功能分析來實現細胞健康篩檢。現代診斷中自動化和人工智慧驅動的分析趨勢，要求技術在保證高精度的同時，最大限度地降低工作流程的複雜性。這使得細胞健康篩檢成為醫院、研究機構和製藥公司的理想選擇。此外，慢性病盛行率的持續上升以及對個人化治療需求的不斷成長，也顯著推動了細胞健康篩檢解決方案的應用。例如，根據個人化醫療聯盟發布的《2024年FDA報告》，美國食品藥物管理局（FDA）在2024年核准了18種新型個人化藥物，約佔新核准治療性分子實體的38%。此外，11種診斷測試系統獲得核准或擴大了適應症，凸顯了個人化醫療和分子診斷領域強勁的監管勢頭和持續創新。

細胞健康篩檢市場：細分分析

全球細胞健康篩檢市場按檢體類型、檢測技術、組件類型、應用領域、最終用戶和地區進行細分。

細胞健康篩檢市場主要分為單細胞分析檢測、多參數細胞檢測及綜合篩檢平台。綜合篩檢平台佔據了相當大的市場佔有率，這得益於其在國家衛生政策和大規模健康篩檢宣傳活動支持的預防性和個人化醫療計畫中的廣泛應用。例如，預計到2025年，全球細胞健康篩檢市場規模將達到約37億美元，其中北美地區約佔50%的市場佔有率，這主要歸功於其先進的醫療保健系統和對篩檢技術的早期應用。單項檢測平台預計將在2024年佔據約79%的市場佔有率，這反映了其在預防性診斷和個人化健康評估中的大規模應用。全球向預防性診斷和個人化健康評估的轉變是由慢性病盛行率上升、人口老化以及人們對早期疾病檢測意識的增強所驅動的。生物標記分析、基因組學和細胞檢測技術的進步使得更有針對性和個人化的健康洞察成為可能，從而加速了這些技術在全球醫療保健系統中的應用。在中國「健康中國2030」醫療衛生現代化計畫、歐盟資助的「地平線歐洲診斷創新計畫」以及美國聯邦政府的預防和精準醫療資金的支持下，醫療服務提供者和診斷公司正擴大採用先進的細胞健康篩檢技術，以支持早期檢測、個人化醫療和大規模預防保健計畫。

按檢體類型分類，血液檢體在細胞健康篩檢市場中佔據顯著佔有率。這主要是由於血液採樣具有微創、經濟高效的特點，廣泛應用於常規預防性診斷和健康促進計畫。在美國精準醫療舉措、中國「健康中國大規模」規劃以及歐盟資助的預防性健康框架等政府主導的支持下，健康診斷、慢性病監測和個人化醫療的蓬勃發展持續推動著對血液細胞檢測和生物標記檢測的需求。同時，唾液和組織檢體是成長最快的類別，這得益於非侵入性診斷、基因組學和細胞層面分析技術的進步，這些技術可用於疾病早期檢測和個人化健康評估。例如，2024年全球細胞健康篩檢市場價值約33億美元，預計2025年底將成長至約35.9億美元。這反映出在政府支持的預防性健康舉措和消費者對早期疾病檢測和個人化健康評估日益成長的需求的推動下，市場正強勁擴張。

細胞健康篩檢市場—區域分析

由於醫療保健現代化和預防性診斷技術在各地區的廣泛應用，細胞健康篩檢市場也呈現顯著的地理差異。歐洲已成為主要的成長中心，這得益於強大的公共醫療保健體系支持下的全民篩檢計畫的擴展，以及對疾病早期檢測的日益重視，並在德國、英國、法國和北歐國家等地推行個性化篩檢舉措。北美地區憑藉先進的診斷基礎設施、高額的醫療保健支出以及聯邦政府對精準醫療和預防醫學的支持，實現了持續成長。東南亞、拉丁美洲和非洲部分地區等新興地區正逐步增強其市場佔有率，這得益於醫療保健服務的改善、慢性病意識的提高以及對診斷檢查室和健康篩檢計畫投資的增加。

由於美國先進的醫療保健基礎設施、預防性診斷的廣泛應用以及對個人化醫療的高度重視，美國細胞健康篩檢市場正經歷強勁成長。 Quest Diagnostics、LabCorp（美國實驗室控股公司）、SpectraCell Laboratories, Inc.、Telomere Diagnostics, Inc. 和 Genova Diagnostics, 主要企業等領先企業持續提供全面的細胞篩檢測試、多組檢測以及生物標記分析服務，用於疾病早期檢測、健康評估和臨床診斷。

例如，全球市場估計預測，細胞健康篩檢市場將從 2024 年的約 33 億美元成長到 2025 年的約 37.3 億美元，其中北美在 2024 年將佔收入佔有率的約 50%，這反映了全球範圍內對基於血液的篩檢和預防性診斷的日益普及。

介紹
北美洲
- 概述
- 北美主要製造商
- 美國
- 加拿大
歐洲
- 概述
- 歐洲主要製造商
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 瑞典
- 俄羅斯
- 波蘭
- 其他
亞太地區
- 概述
- 亞太地區主要製造商
- 中國
- 印度
- 日本
- 韓國
- 澳洲
- 印尼
- 泰國
- 菲律賓
- 其他
拉丁美洲
- 概述
- 拉丁美洲主要製造商
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 其他
中東和非洲
- 概述
- 中東和非洲的主要製造商
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- 其他

第13章主要供應商分析－細胞健康篩檢產業

競爭對手儀錶板
- 競爭基準
- 競爭定位
公司簡介
- Telomere Diagnostics, Inc.
- SpectraCell Laboratories, Inc.
- Life Length
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings（LabCorp）
- Genova Diagnostics
- Cell Science Systems
- Repeat Diagnostics, Inc.
- Immundiagnostik AG
- DNA Labs India
- Others

第14章：分析師視角360度分析

簡介目錄

Product Code: ANV6041

Cellular Health Screening Market size was valued at US$ 3,298.09 Million in 2024, expanding at a CAGR of 9.45% from 2025 to 2032.

Cellular Health Screening involves analyzing cells at the molecular and functional level to detect abnormalities, monitor health status, and guide therapeutic interventions. The growing demand for early disease detection, personalized medicine, and drug development is driving the adoption of cellular health screening technologies. Opportunities exist in developing high-throughput, accurate, and non-invasive screening platforms, essential for applications in cancer diagnostics, infectious disease detection, and precision therapy. A prominent trend is the integration of automation and AI-based analysis to improve efficiency and accuracy. However, high costs and complex workflows, particularly for advanced molecular and imaging-based screening, limit widespread adoption in smaller clinics and emerging regions.

Cellular Health Screening Market- Market Dynamics

Growing adoption of personalized medicine

Personalized medicine refers to a healthcare approach that customizes medical treatment based on a patient's genetic information, biomarkers, and individual health data. It focuses on providing targeted therapies and precise interventions for better outcomes and reduced side effects. The growing adoption of advanced healthcare diagnostics and personalized medicine is significantly driving the demand for cellular health screening technologies, which play a critical role in early disease detection, monitoring patient health, and guiding treatment decisions. As healthcare providers increasingly focus on precision therapies and preventive care, laboratories and clinics face the need for accurate, high-throughput, and reliable screening platforms, which cellular health screening solutions provide through detailed cellular analysis, biomarker detection, and functional assays. The trend toward automation and AI-enabled analysis in modern diagnostics demands technologies that offer high accuracy while minimizing workflow complexity, making cellular health screening an ideal choice for hospitals, research institutes, and pharmaceutical companies. Moreover, the continuous growth in chronic disease prevalence and the rising demand for personalized treatment are significantly increasing the adoption of cellular health screening solutions. For instance, according to the Personalized Medicine Coalition's 2024 FDA report, the U.S. Food and Drug Administration approved 18 new personalized medicines in 2024, representing about 38 % of all newly approved therapeutic molecular entities and cleared or expanded indications for 11 diagnostic testing systems, underscoring strong regulatory momentum and continued innovation in personalized treatment and molecular diagnostics.

Cellular Health Screening Market- Segmentation Analysis:

The Global Cellular Health Screening Market is segmented on the basis of Sample Type, Testing Technology, Component Type, Application Area, End User, and Region.

The Cellular Health Screening market is primarily categorized into single-cell analysis tests, multi-parameter cellular assays, and integrated screening panels. Among these, integrated screening panels account for a significant share of revenue, mainly because they are widely adopted in preventive healthcare and personalized medicine programs supported by national health initiatives and large-scale wellness screening campaigns. For example, in 2025, the global Cellular Health Screening market is estimated to be worth around USD 3.7 billion, with North America capturing about 50% of the market revenue due to advanced healthcare systems and early adoption of screening technologies. The single-test panels segment accounted for roughly 79% of market share in 2024, reflecting broad use in preventive diagnostics and personalized health assessments. The massive global shift toward preventive diagnostics and personalized health assessments is driven by rising chronic disease prevalence, aging populations, and increasing awareness of early disease detection. Advances in biomarker analysis, genomics, and cellular testing are enabling more targeted, individualized health insights, accelerating adoption across healthcare systems worldwide. Under China's Healthy China 2030 healthcare modernization initiative, EU-funded Horizon Europe diagnostic innovation programs, and U.S. federal preventive healthcare and precision medicine funding, healthcare providers and diagnostics companies are increasingly adopting advanced cellular health screening technologies to support early detection, personalized care, and large-scale preventive health programs.

Based on the sample type segment, blood-based samples recorded a notable share in the Cellular Health Screening market, mainly because blood collection is minimally invasive, cost-effective, and widely used across routine preventive diagnostics and wellness programs. The large-scale expansion of health check-ups, chronic disease monitoring, and personalized medicine supported by government initiatives such as the U.S. Precision Medicine Initiative, China's Healthy China 2030 program, and EU-funded preventive healthcare frameworks continues to push demand for blood-based cellular assays and biomarker testing. Whereas, saliva- and tissue-based samples represent the fastest-growing category, driven by advancements in non-invasive diagnostics, genomics, and cell-level analysis for early disease detection and personalized health assessment. For instance, the global cellular health screening market was valued at approximately $3.30 billion in 2024 and was projected to grow to around $3.59 billion by the end of 2025, reflecting strong market expansion driven by government-backed preventive health initiatives and increasing consumer demand for early disease detection and personalized health assessments.

Cellular Health Screening Market- Geographical Insights

The Cellular Health Screening market also shows notable geographical variation, driven by regional healthcare modernization and preventive diagnostics adoption. Europe emerges as a key growth hub, supported by strong public healthcare systems, rising focus on early disease detection, and personalized medicine initiatives in countries such as Germany, the United Kingdom, France, and the Nordic nations, where population-wide screening programs are expanding. North America registers sustained growth, propelled by advanced diagnostic infrastructure, high healthcare spending, and federal initiatives supporting precision medicine and preventive care. Emerging regions, including Southeast Asia, Latin America, and parts of Africa, are gradually strengthening their market presence, fueled by improving healthcare access, increasing chronic disease awareness, and growing investments in diagnostic laboratories and wellness screening programs.

United States' Cellular Health Screening market is recording robust growth, supported by the country's advanced healthcare infrastructure, widespread preventive diagnostics adoption, and strong focus on personalized medicine. Key players such as Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (LabCorp), SpectraCell Laboratories, Telomere Diagnostics, and Genova Diagnostics continue to supply comprehensive cellular screening tests, multi-panel panels, and biomarker analysis services for early disease detection, wellness assessment, and clinical diagnostics.

For instance, according to global market estimates, the Cellular Health Screening market grew from approximately USD 3.30 billion in 2024 to about USD 3.73 billion in 2025, with North America holding nearly 50% of the revenue share in 2024, reflecting strong uptake of blood-based screening and preventive diagnostics worldwide.

Cellular Health Screening Market- Competitive Landscape:

The industry is moderately concentrated, with several key service providers dominating the competitive landscape. Leading players include Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (LabCorp), SpectraCell Laboratories, Telomere Diagnostics, and Genova Diagnostics. These organizations compete through continuous innovation in screening technologies and assay platforms, focusing on higher sensitivity, expanded biomarker panels, faster turnaround times, and integrated data analytics to meet the evolving demands of preventive healthcare, personalized medicine, and clinical diagnostics. For instance, in January 2025, SpectraCell Laboratories launched the new Cellular Stress Panel, designed to assess oxidative stress, inflammation markers, and mitochondrial efficiency. This advanced test provides comprehensive cellular health insights for clinical diagnostics and wellness applications, supporting preventive care and personalized medicine. Companies in the Cellular Health Screening market also focus on expanding product portfolios to cover diverse screening panels and assays for applications such as preventive diagnostics, personalized therapy, drug development, and wellness monitoring.

Recent Developments:

In October 2023, DELFI Diagnostics launched 'FirstLook Lung', a blood test for early lung cancer detection using low dose CT with a 99.7% negative predictive value (NPV), enhancing personalized diagnostic accuracy.

In 2024, industry innovators introduced multi marker and AI enabled screening solutions, including a combined telomere, mitochondrial, inflammation, and epigenetic age panel and the AI based LungOI NSCLC molecular panel, improving depth and speed of cellular health insights.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CELLULAR HEALTH SCREENING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Telomere Diagnostics, Inc.
SpectraCell Laboratories, Inc.
Life Length
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings (LabCorp)
Genova Diagnostics
Cell Science Systems
Repeat Diagnostics, Inc.
Immundiagnostik AG
DNA Labs India
Others

GLOBALCELLULAR HEALTH SCREENING MARKET, BY SAMPLE TYPE - MARKET ANALYSIS, 2019 - 2032

Blood Samples
Saliva Samples
Tissue Biopsies
Urine Samples
Other Biological Fluids

GLOBAL CELLULAR HEALTH SCREENING MARKET, BY TESTING - MARKET ANALYSIS, 2019 - 2032

Flow Cytometry
Molecular Diagnostics (PCR, qPCR)
Next-Generation Sequencing (NGS)
Cell-Based Assays
Microscopy & Imaging Systems
Biosensor-Based Technologies
AI & Machine Learning-Enabled Platforms

GLOBAL CELLULAR HEALTH SCREENING MARKET, BY COMPONENT TYPE - MARKET ANALYSIS, 2019 - 2032

Single Marker Panels
Multi-Marker Panels
Genomic & Telomere Panels
Epigenetic Screening Panels
Cell Stress & Functional Assays
AI-Assisted Analytical Modules

GLOBAL CELLULAR HEALTH SCREENING MARKET, BY APPLICATIONS AREA - MARKET ANALYSIS, 2019 - 2032

Early Disease Detection & Diagnosis
Preventive Health Screening
Personalized Medicine / Precision Therapy
Chronic Disease Management
Drug Discovery & Development
Aging & Longevity Assessment
Wellness & Lifestyle Monitoring

GLOBAL CELLULAR HEALTH SCREENING MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutes
Pharmaceutical & Biotechnology Companies
Home Healthcare Providers
Preventive Health Centers & Wellness Clinics

GLOBAL CELLULAR HEALTH SCREENING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Cellular Health Screening Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Cellular Health Screening Market Snippet by Sample Type
- 2.1.2. Cellular Health Screening Market Snippet by Testing Technology
- 2.1.3. Cellular Health Screening Market Snippet by Component Type
- 2.1.4. Cellular Health Screening Market Snippet by Application Area
- 2.1.5. Cellular Health Screening Market Snippet by End User
- 2.1.6. Cellular Health Screening Market Snippet by Country
- 2.1.7. Cellular Health Screening Market Snippet by Region
2.2. Competitive Insights

3. Cellular Health Screening Key Market Trends

3.1. Cellular Health Screening Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Cellular Health Screening Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Cellular Health Screening Market Opportunities
3.4. Cellular Health Screening Market Future Trends

4. Cellular Health Screening Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Cellular Health Screening Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Cellular Health Screening Market Landscape

6.1. Cellular Health Screening Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Cellular Health Screening Market - By Sample Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Sample, 2024 & 2032 (%)
- 7.1.2. Blood Samples
- 7.1.3. Saliva Samples
- 7.1.4. Tissue Biopsies
- 7.1.5. Urine Samples
- 7.1.6. Other Biological Fluids

8. Cellular Health Screening Market - By Testing Technology

8.1. Overview
- 8.1.1. Segment Share Analysis, By Testing, 2024 & 2032 (%)
- 8.1.2. Flow Cytometry
- 8.1.3. Molecular Diagnostics (PCR, qPCR)
- 8.1.4. Next Generation Sequencing (NGS)
- 8.1.5. Cell Based Assays
- 8.1.6. Microscopy & Imaging Systems
- 8.1.7. Biosensor Based Technologies
- 8.1.8. AI & Machine Learning Enabled Platforms

9. Cellular Health Screening Market - By Component Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Component, 2024 & 2032 (%)
- 9.1.2. Single Marker Panels
- 9.1.3. Multi Marker Panels
- 9.1.4. Genomic & Telomere Panels
- 9.1.5. Epigenetic Screening Panels
- 9.1.6. Cell Stress & Functional Assays
- 9.1.7. AI Assisted Analytical Modules

10. Cellular Health Screening Market - By Application Area

10.1. Overview
- 10.1.1. Segment Share Analysis, By Testing, 2024 & 2032 (%)
- 10.1.2. Early Disease Detection & Diagnosis
- 10.1.3. Preventive Health Screening
- 10.1.4. Personalized Medicine / Precision Therapy
- 10.1.5. Chronic Disease Management
- 10.1.6. Drug Discovery & Development
- 10.1.7. Aging & Longevity Assessment
- 10.1.8. Wellness & Lifestyle Monitoring

11. Cellular Health Screening Market - By End User

11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 11.1.2. Hospitals & Clinics
- 11.1.3. Diagnostic Laboratories
- 11.1.4. Research & Academic Institutes
- 11.1.5. Pharmaceutical & Biotechnology Companies
- 11.1.6. Home Healthcare Providers
- 11.1.7. Preventive Health Centers & Wellness Clinics

12. Cellular Health Screening Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Cellular Health Screening Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Sample, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Testing, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
- 12.2.10. Canada
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Cellular Health Screening Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Sample, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Testing, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
- 12.3.10. UK
- 12.3.11. France
- 12.3.12. Italy
- 12.3.13. Spain
- 12.3.14. The Netherlands
- 12.3.15. Sweden
- 12.3.16. Russia
- 12.3.17. Poland
- 12.3.18. Rest of Europe
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Cellular Health Screening Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Sample, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Testing, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. China
- 12.4.10. India
- 12.4.11. Japan
- 12.4.12. South Korea
- 12.4.13. Australia
- 12.4.14. Indonesia
- 12.4.15. Thailand
- 12.4.16. Philippines
- 12.4.17. Rest of APAC
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Cellular Health Screening Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Sample, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Testing, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
- 12.5.10. Mexico
- 12.5.11. Argentina
- 12.5.12. Colombia
- 12.5.13. Rest of LATAM
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Cellular Health Screening Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Sample, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Testing, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.10. UAE
- 12.6.11. Israel
- 12.6.12. Turkey
- 12.6.13. Algeria
- 12.6.14. Egypt
- 12.6.15. Rest of MEA

13. Key Vendor Analysis- Cellular Health Screening Industry

13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. Telomere Diagnostics, Inc.
- 13.2.2. SpectraCell Laboratories, Inc.
- 13.2.3. Life Length
- 13.2.4. Quest Diagnostics Incorporated
- 13.2.5. Laboratory Corporation of America Holdings (LabCorp)
- 13.2.6. Genova Diagnostics
- 13.2.7. Cell Science Systems
- 13.2.8. Repeat Diagnostics, Inc.
- 13.2.9. Immundiagnostik AG
- 13.2.10. DNA Labs India
- 13.2.11. Others